Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ESRRA | P11474 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 4/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597718 | 0.80 | KDM4E (0.65) | KDM4EALDH1A1L3MBTL1POLBNPC1 | |
| SCHEMBL16838774 | 0.80 | KDM4E (0.65) | KDM4EALDH1A1L3MBTL1POLBNPC1 | |
| SCHEMBL6198763 | 0.78 | L3MBTL1 (0.66) | KDM4EALDH1A1L3MBTL1POLBNPC1 | |
| SCHEMBL4598575 | 0.78 | HRH3 (0.46) | ALDH1A1ESRRASLC22A12MRGPRX4AR | |
| SCHEMBL16838773 | 0.77 | ALDH1A1 (0.65) | KDM4EALDH1A1L3MBTL1POLBNPC1 | |
| SCHEMBL16838779 | 0.77 | KDM4E (0.65) | KDM4EALDH1A1L3MBTL1POLBNPC1 | |
| SCHEMBL4597870 | 0.77 | ALDH1A1 (0.60) | KDM4EALDH1A1L3MBTL1POLBNPC1 | |
| SCHEMBL3163774 | 0.76 | ALDH1A1 (0.61) | KDM4EALDH1A1L3MBTL1POLBHRH3 | |
| SCHEMBL3223757 | 0.76 | KDM4E (1.00) | KDM4EALDH1A1L3MBTL1POLBNPC1 | |
| SCHEMBL4718693 | 0.76 | HRH3 (0.38) | KDM4EL3MBTL1ESRRASLC22A12MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924265-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | Genzyme Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | KDM4E 3689/4885ALDH1A1 3484/4885L3MBTL1 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.